Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Ghaderi, A
The primary composite outcome of major adverse cardiac events plus (MACE+), including death from CV causes, nonfatal MI, and hospitalization for unstable angina, was reached in 13.4% of patients in the lixisenatide group and 13.2% of patients in placebo group, demonstrating noninferiority, but not superiority, of lixisenatide compared with placebo
Bee Immune helps with the frequency and duration of respiratory immune challenges
Gomes MB, Negrato CA
US$ 27.48
US$ 26.16
US$ 25.09
US$ 27.58
US$ 28.99
US$ 29.40
US$ 24.32
US$ 29.34
US$ 22.44
US$ 21.82
.webp)
US$ 23.23
US$ 20.60
US$ 28.19
